T-cell prolymphocytic leukemiaNews & Research
8 curated articles for T-cell prolymphocytic leukemia — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Haematologica Apr 23, 2026
Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT.
Not available.
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
- Annals of hematology Apr 12, 2026
A case of T-prolymphocytic leukemia harboring RAS mutation.
The text reports the clinical case of a 61-year-old woman with a long history of generalized pruritus who was eventually diagnosed with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive T-cell lymphoproliferative disorder. At presentation, the patient had fever, skin lesions, lymphocytos...
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
- Leukemia & lymphoma Apr 6, 2026
Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study.
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive malignancy with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HCT) is often used for treatment, but its effectiveness remains unclear. In this study of 33 adult patients with T-PLL who underwent HCT, 5-year progr...
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
- Cancers Mar 28, 2026
How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas.
T-cell non-Hodgkin lymphomas, which arise from post-thymic mature T cells, constitute approximately 10-15% of all non-Hodgkin lymphomas. Their leukemic presentations, referred to here as mature T-cell leukemias, are relatively uncommon and present significant diagnostic and therapeutic challenges re...
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
- Journal of cutaneous pathology Mar 9, 2026
Cutaneous-Only Relapse in T-Cell Prolymphocytic Leukemia With JAK2 Rearrangement.
Cutaneous-Only Relapse in T-Cell Prolymphocytic Leukemia With JAK2 Rearrangement.
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
- International journal of laboratory hematology Mar 3, 2026
Splenic B-Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement.
Splenic B-cell lymphoma/leukemia includes a group of indolent small B-cell lymphomas/leukemias that share overlapping morphological and immunophenotypic features, making accurate diagnosis challenging. Specific gene rearrangements have not been commonly associated with splenic B-cell lymphomas/leuke...
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
- Journal of hematology Mar 2, 2026
A Rare Presentation of T-cell Prolymphocytic Leukemia With Abnormal Uterine Bleeding.
T-cell prolymphocytic leukemia (T-PLL) is a rare and clinically aggressive T-cell neoplasm, which is composed of lymphoid cells that are of post-thymic T-cell origin. This is a case of a 57-year-old female with no significant medical history, who presented with a 4-month history of facial swelling, ...
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
- Blood neoplasia Jan 15, 2026
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.
T-cell prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm with an aggressive clinical course. Overall prognosis is poor, and treatment relies on alemtuzumab because of inadequate response to conventional chemotherapy. Three-quarters of cases harbor activating mutations in the JAK-STAT pathw...
Why it matters: Recent peer-reviewed research on T-cell prolymphocytic leukemia that may be relevant for patients and caregivers.
More on T-cell prolymphocytic leukemia
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.